Browsing Tag
Pfizer
118 posts
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
Pfizer-backed Priovant wins FDA priority review for brepocitinib in dermatomyositis
FDA grants priority review to Priovant's brepocitinib NDA for dermatomyositis with a Q3 2026 PDUFA date. Read what this means for Roivant, Pfizer, and the autoimmune market.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard
Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards.